ROIV - Roivant Sciences Ltd

29.52
1.670   5.657%

Share volume: 9,607,090
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.72%

PREVIOUS CLOSE
CHG
CHG%
$27.85
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
42%
Profitability 35%
Dept financing 23%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
5.05%
1 Month
39.64%
3 Months
40.77%
6 Months
128.48%
1 Year
175.89%
2 Year
154.48%
Key data
Stock price
$29.52
P/E Ratio 
0.00
DAY RANGE
$28.19 - $29.83
EPS 
-$0.61
52 WEEK RANGE
$8.73 - $29.83
52 WEEK CHANGE
$178.49
MARKET CAP 
15.092 B
YIELD 
N/A
SHARES OUTSTANDING 
715.701 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-07-2025
BETA 
0.76
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$5,276,846
AVERAGE 30 VOLUME 
$7,123,680
Company detail
CEO: Matthew Gline
Region: US
Website: roivant.com
Employees: 860
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company that researches and develops medicines. The company was founded in 2014 and is based in London, the United Kingdom.

Recent news